Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
169 Cards in this Set
- Front
- Back
what is : ability of immune system to mount an antigen specific immune rxn?
|
adaptive immunity
|
|
what are the cells involved in adaptive immunity?
|
T cells
B cells antigen presenting cells cytokines macs/eosinophils/basophils/PMNs |
|
what's the humoral response?
|
B lymphocytes make antibodies
|
|
CD4 + T helper cells- make lots of cytokines = imp for : _________
|
regulating mac and neutrophil activation; also help regulate B cell antibody production
|
|
who does this: recog cells infected w/ endogenous viruses or mutated cells (cancer); imp in mediating viral clearance, intracellular pathogens like mycoplasma ?
|
CD8 T cells
|
|
are natural killers B or T?
|
NEITHER!
|
|
where do NK cells circulate?
|
peripheral blood
|
|
how do NK recognize cells?
|
with IgG Fc receptor
|
|
What cells do NK recognize and kill?
|
IgG coated target cells : Type 2 hypersensitivity ADCC
|
|
NK cells have an inhibitory receptor to recognize:
|
MHC class I molecule
|
|
what does the NK activating receptor recognize?
|
stress proteins
viral proteins |
|
what are the tumor defense cells?
|
NK cells
|
|
what do NK T cells express?
|
alpha/beta TCR and CD4 or CD8
NK cell markers |
|
how are CD4 NK-T cells polarized?
|
Th1 or Th2
|
|
what do the CD4 NK-T cells express?
|
IFN-gamma
IL-4 |
|
tumor cells downregulate __________ molecules to evade CD8
|
MHC I
|
|
what's this:
Via cell:cell contact and cytokine release, these T-cells function primarily through regulation of other effector cells: B-cells, Phagocytic cells? |
CD4+
|
|
what's Lost in HIV?
|
CD4+
|
|
what are the different subsets of CD4+?
|
Th1, Th2, Th17, Treg
|
|
what Acts directly on infected or altered cells (e.g. viral infection and tumor surveillance). ??
|
CD8+
|
|
what cells are present at high numbers in mucosa of asthmatics?
|
CD4+/Th2 NK-T cells
|
|
what are general proinflammatory cytokines?
|
IL-1, TNF-a
|
|
what are general antiinflammatory/repair cytokines?
|
TGF-b, IL-10
|
|
what are cytokines that encourage proliferation?
|
IL-2
|
|
what are cytokines imp for differentiation?
|
IL-7 (B-/T-cell maturation); IL-4 (Th2);
IL-12 (Th1); TGF-b & IL-23 (Th17) |
|
what activates endothelial cells, upregulate adhesion molecules so white cells go to areas of activation; activate liver to induce acute phase reactant proteins; induces febrile response ?
|
TNF alpha
|
|
what cytokines does Th1 lead to?
|
IFN-g/IL-2/IL-12
|
|
what cytokines does Th2 lead to?
|
IL-4/5
|
|
what cytokines does Th17 lead to?
|
IL-17/chemokines
|
|
what cytokine is associated w/ Cell mediated immunity effector cells (macrophages, NK cells)?
|
IFN- gamma
|
|
what cytokines are Humoral & IgE mediated effector cells (MAST cells, eosinophils) ass w/?
|
IL-4, IL-5
|
|
what are the steps in a B cell receptor growing up?
|
Ig H & L chain = Signal 1
Variable region = Ag specificity Signal 2 = Complement C3b binding |
|
Monoclonality in B cells is useful
clinically to demonstrate? |
neoplasia
|
|
Variable region rearrangement and hypermutability of B cells(Both H & L chains) necessary for?
|
1. Ag specificity
2. Ag binding to BCR 3. Hypermutability of variable region 4. Malignancy: |
|
Variable region rearrangement and hypermutability of B cells(Both H & L chains) necessary for Ag specificity?
|
(e.g. cross reaction with self Ags would induce autoimmune disease)
|
|
why is Variable region rearrangement and hypermutability (Both H & L chains) of b cell necessary for:Ag binding to BCR ?
|
induces proliferation of B-cell; thus, selecting for B-cells with greatest BCR affinity to Ag
|
|
why is Variable region rearrangement and hypermutability (Both H & L chains) of b cell necessary for:hypermutability ?
|
Hypermutability of variable region (via RAG-mediated recombination) + Positive selection (#2 above) ensure “Affinity maturation” or continual production of Ab’s with greater affinity and specificity.
|
|
why is Variable region rearrangement and hypermutability (Both H & L chains) of b cell necessary for:malignancy ?
|
Malignancy: Monoclonal BCR clone rearrangement by molecular testing or monoclonal Ab production by electrophoresis.
|
|
when does B cell receptor require double signal for activation?
|
1. Coupling of BCR with Ag
2. Binding of CD21 with complement C3b |
|
what are the TCR heterodimers?
|
alpha/beta (95%) and gamma/delta
|
|
what is useful for immunophenotyping as T-cell
& T-cell subsets ? |
CD3, CD4, CD8
|
|
Variable and constant region of TCR formed by _____________
|
TCR somatic rearrangement
|
|
monoclonality of T cells linked to :
|
neoplasia
|
|
T cell alpha/beta Co-express : ______________
|
CD4 or CD8: Ag presentation MHC restricted
|
|
T cell gamma/delta express:
|
CD4/CD8 (-) or weak CD8: Targeted to mucosal / epidermal surfaces: Wound repair/tumor surveillance?
|
|
Like the BCR, the TCR has a variable region responsible for
|
Ag-specific activation.
|
|
Again, like the BCR, the TCR undergoes a high rate of recombination events to
|
generate Ag diversity.
|
|
The presence of a monoclonal TCR population is an indication of a:
|
T-cell neoplastic process.
|
|
what is useful for: immunophenotyping or ID’ing T-cells in tissues or by flow cytometry.?
|
The constant CD3 protein that is a part of the TCR complex
|
|
CD4+ cells are responsive to Ag presented by :
|
MHCII expressing APCs
|
|
CD8+ cells are responsive to Ag presented by
|
MHCI expressing cells.
|
|
A secondary signal elicited by CD80 (B7.1) or CD86 (B7.2) binding to the T-cell CD28 receptor is necessary for________ and can lead to _________
|
necessary for activation & can lead to anergy.
|
|
Once activated, T-cells may express an inhibitory CD80/86 receptor called
|
CTLA-4
|
|
most of T cells are what type?
|
CD4+ : 60%
|
|
what are the First T cells activated by phagocytic cells of innate immunity.?
|
CD4+
|
|
MHC II mediates presentation of what?
|
processed exogenous peptides (APC cells)
|
|
what are the CD4+ Tcells a heterodimer of?
|
a/b HLA-DP, DQ, DR proteins
|
|
which T cells does HIV exhibit tropism for/take out?
|
CD4+
|
|
I Recognize endogenously synthesized
peptides in concert with MHC Class I (All nucleated cells): who am I? |
CD8+ T cells
|
|
what are CD8+ T cells heterodimer?
|
b-2 microglobulin + A, B, or C
HLA protein |
|
fun fact!
|
b-2 microglobulin: hemodialysis associated amyloidosis
|
|
what induces T cell lymphocyte prolif; in some tumor types like melanoma, give IL-2 to stim immune rxn against tumor?
|
proliferative cytokines
|
|
what is imp in regulating cell mediated immunity like macs and NK cells?
|
IFN- gamma
*also induces normal nucleated cells to upregulate MHC I molecs so you get more effective CD8 cell mediate immunity |
|
ppl who are prone to allergies have more _________ and less _____________
|
more IL-4 and much less of Th1 cytokines , interferon gamma
|
|
may play imp role in reg chronic inflamm conditions like crohn’s or ulcerative colitis
|
Th17
|
|
what are the steps of B cell activation?
|
when antigen binds to receptor, induces dimerization; if secondary signal w/ complement C3b binding to CD21 receptor will induce internalization and activation of B cell to make IgM (naive B cell)
IgM made during 1st time B cell introduced to antigen also triggers MHCII upregulation.. B cell will present antigen to CD4 T cell that also recog antigen |
|
describe B cell activation for T cell independent antigens?
|
(e.g. Pokeweed mitogen &
Carbohydrate antigens) Induce low affinity IgM and no memory cells |
|
how do you get Hyper IgM immunodeficiency Syndrome in B cell activation?
|
Absence of CD40L/CD40
|
|
Ag & C3b binding to the BCR of a naïve B-cell (in the absence of a T-cell response) is only capable of producing :
|
IgM
*Class switching to IgG/IgA and affinity maturation that selects for B-cells with higher affinity IgG/IgA will not occur. |
|
Plasma cell differentiation and memory B-cells are also not formed without:
|
T-cell interaction
|
|
This B-cell/T-cell interaction is also important in preventing :
|
Ag production to self-Ag’s, as it is unlikely that both BCR and TCR’s with self-Ag specificity will be present.
|
|
Ag processing and presentation of Ag by the B-cell (now an APC) through its MHCII molecule to a TCR with Ag specificity will ensure :
|
B-cell class switching, etc.
|
|
what requires binding of the B-cell CD40 receptor to CD40 ligand (CD40L) on T-cells?
|
Ag processing for B cell activation
|
|
absence of the CD40L or CD40 is the basis for what disease?
|
the immunodeficient disorder, hyper-IgM syndrome.
|
|
Th1 cytokines (e.g. IFNg) are very important in regulating :
|
cell-mediated responses to viral infections, graft rejections and tumor immune-surveillance.
|
|
Poorly controlled Th1 responses are important in :
|
graft rejection, chronic inflammatory disorders, and autoimmune (AI) diseases with primarily a cell-mediated component.
|
|
Th2 T-cells and cytokines are highly expressed in individuals prone to :
|
allergies (atopic individuals).
|
|
The type I hypersensitivity response (e.g. anaphylaxis) is dependent on :
|
Th2 polarized (exaggerated) responses.
|
|
what induces Th17 development?
|
IL-23 induces Th17 development in humans (TGF-b and IL-6 appear to be more important in mice).
|
|
what Appears to be important in production of cytokines important in granulocyte recruitment and extracellular bacterial/fungal infections.?
|
Th17
|
|
what appears to play role in chronic inflammatory disease and autoimmune disorders (e.g. Crohn’s, Rheumatoid arthritis, Psoriasis).
|
Th1
Th17 |
|
is Th17 susceptible to inhibition by Treg cells?
|
barely
|
|
what's Th17 development blocked by?
|
Th2 cytokine IL-4
|
|
what does Treg Act to inhibit ?
|
Th1/ Th2
|
|
what's Very important in preventing AI disease and chronic inflammatory disease?
|
Treg
|
|
Neoplastic disease often recruits and drives the differentiation of T-cells to the: _________
|
Treg phenotype to prevent the immune system from mounting a response.
|
|
what are basic differences b/w immature and mature APC?
|
Immature APC:
CD80/86 (B7.1/7.2) Low Activated APC: High CD80/86 + Ag presentation MHCI &II |
|
inhibits Th1 and Th2 actions by making TGFbeta and express inhibitory receptors; induce lots of fibrosis- who am I?
|
T reg cell
|
|
FoxP3 essential for development, won’t turn into Treg cells w/o it; if suppress FoxP3, get _______
|
severe systemic immune disease
|
|
where do dendritic cells hangout?
|
: hang out in submucosa or subepithelial areas in dermis.. waiting for bac to invade into subepithelial space
|
|
are dendritic cells professional?
|
very!
|
|
what happens once immature APC sees bac?
|
gobbles up bac, processes it along w/ MHCI AND II and upregulates CD80/86
also becomes migratory to draining lymph nodes.. hang out in same areas as T cells, presenting antigens to T cells |
|
where does APC go for Presentation
of Ag to CD4 & CD8 cells? |
lymph node
|
|
what type of APCs inhabit subepithelial spaces?
|
Immature or Naïve professional APCs (dendritic cells)
|
|
Immature APCs express low levels of ___________
|
CD80/86 (B7.1/7.2) and MHC molecules
|
|
when are APCs activated?
|
when eat pathogen
|
|
what's result of APC activation?
|
motile phenotype and migration to draining LNs under control of specific chemokines and chemokine receptors expressed on T-cells and APCs
*up-regulation of CD80/86 and MHC molecules for presentation of Ag to naïve T-cells within the LN |
|
how are antigens presented to T cells by APCs in lymph node?
|
often within the high endothelial venules which express adhesion molecules that are expressed by both T-cells and activated APCs (e.g. ICAM-1)).
|
|
what happens to APC when presentation of Ag in the absence of CD80/86 interaction with the T-cell CD28 receptor ?
|
anergy (inability of the T-cell to respond to Ag challenge)
|
|
why is anergy of T cell important?
|
key in maintaining peripheral tolerance (e.g. inducing T-cell anergy to self Ag exposure in absence of an inflammatory insult)
|
|
AI disease is commonly associated with ___________
|
proviral disease
|
|
a proviral syndrome could induce APC maturation at a time when self-Ags may also being presented to T-cells – resulting in:
|
an inappropriate AI response.
|
|
what's the purpose of central T cell tolerance?
|
Clonal deletion of self-reactive T cells in thymus.
|
|
what's 1st step in central T cell tolerance?
|
Positive selection for T-cells recognizing MHC molecules (cells lacking recognition are deleted).
|
|
what's 2nd step in central T cell tolerance?
|
Second: Negative selection for cells with high affinity interaction with self antigens (cells deleted).
|
|
Some T-cells that recognize self Ag are converted to ________
|
Treg cells.
|
|
what Transcriptional regulator induces “peripheral Ag” expression in thymic cells
(Mutated in autoimmune polyendocrinopathy)? |
AIRE (Autoimmune regulator)
|
|
: low MHC Class I & II and B7 co-stimulatory molecules is common in what?
|
immature APC cells
|
|
: Activation by microbial molecules or proteins
released from necrotic cells: Increased MHC & B7 is common in what? |
mature APC cells
|
|
what also expresses
inhibitory B7 receptor, CTLA-4 ((-/-) mice assoc. with AI disease) Polymorphisms assoc. with human AI disease? |
T cells
|
|
up-regulation of CTLA-4 on T-cells and recruitment of FoxP3+ Tregs is to : ____________ (malicious act)
|
shield the tumor
|
|
Absent CD80/86 binding during Ag presentation to TCR results in :
|
anergy
|
|
AI disease is frequently preceded by what?
|
viral infection leading to idea that virally-mediated activation of APCs results in a bystander or coincidental activation of autoreactive T-cells
|
|
!!
|
Ab’s against CD80/86 have shown promise as co-therapy with tumor vaccines.
|
|
what is overexpressed on many Treg cells and is also up-regulated in other T-cells following Ag-induced activation?
|
CTLA-4
|
|
CTLA-4 receptor exhibits much higher affinity for __________, thus inhibiting the actions of _________ leading to loss of ___________
|
CTLA-4 receptor exhibits much higher affinity for CD80/86, thus inhibiting the actions of CD28 leading to loss of T-cell activity or anergy
|
|
what transcription factor is necessary for Treg differentiation?
|
FoxP3
|
|
what's the result in animal w/ no Treg gene?
|
AI disease
|
|
Tregs suppress what? how?
|
Tregs appear to suppress Th1/Th2 responses through at least several mechanisms, including production of anti-inflammatory cytokines (TGF-b/IL-10) and via high expression of CTLA-4.
|
|
Activated T-cells express high /low levels of Fas ligand (FasL)
|
high!
|
|
when a previously activated T-cell reencounter Ag presentation to the TCR complex AND the other cell expresses Fas. Fas:FasL interaction in turn results in apoptosis- what is this??
|
activation induced cell death of T cell
|
|
mutated FAS in humans results in:
|
Autoimmune Lymphoproliferative Syndrome
|
|
Immune privileged sites (testes, brain, eye, pregnant uterus) utilize high/low levels of Fas, along with high/low expression of MHC molecules (no mature APCs, thus anergy),
|
Immune privileged sites (testes, brain, eye, pregnant uterus) utilize HIGH levels of Fas, along with LOW expression of MHC molecules (no mature APCs, thus anergy),
|
|
Immature B-cells exposed to high levels of circulating self antigens undergo receptor editing (BCR rearrangements in hypervariable region that do not recognize self).
If not successful, undergo apoptosis - WHAT'S THIS? |
central B cell tolerance
|
|
Requires T-cells. Ag must also be
recognized by Th cells to stimulate B-cell development. (Remember CD40:CD40L interaction?) - WHAT'S THIS? |
peripheral B cell tolerance
|
|
*know table on allergy types
|
:)
|
|
what are the primary mediators of the allergic response?
|
Histamine (Antihistamines):
Chemotactic factors: (LTB4, Eosinophil chemotactic factor) |
|
what are secondary mediators (lipid) of allergic response?
|
Cysteinal Leukotrienes (C4, D4), PGD2, PAF
CysLT1 receptor antagonists: zafirlukast (Accolate), montelukast (Singulair). 5-LO inhibitors: Zileuton (Zyflow) |
|
what are secondary mediators (cytokines) of allergic response?
|
TNF
IL-4, IL-5 |
|
what's the early response to Type I allergic rxn?
|
Wheel and flare / bronchospasm (LKT C4/D4, PAF) and mucous hypersecretion: vasodilation (histamine, PAF); vascular permeability (histamine, PAF, LKT C4/D4).
|
|
what's late response to Type I allergic rxn?
|
Recruitment of eosinophils, basophils, neutrophils, CD4+ (TH2). Tissue remodeling
|
|
what are some bad effects of asthma?
|
Basement membrane thickening
mucus plug Inflammation with eosinophils Also: CD4+/Th2 NK-T cells |
|
basically, what's a type II hypersensitivity rxn?
|
In all cases:
Immune reaction against Ab/complement bound to cell or tissue |
|
Ab binding to Ag on cell results in complement fixation and opsonization, resulting in lysis or phagocytosis (e.g. transfusion reaction, AI hemolytic anemia, AI thrombocytopenia)
- what's this? |
Type II: Cytotoxic Antibody Mediated
|
|
Ab binding to cells activates effector cells: NK cells & also Monocytes, PMNs, Eosinophils, that lyse Ag-coated cells via cytotoxic mechanisms (e.g. granzyme/perforin) (No phagocytosis). Eos use this mechanism to destroy parasites.
- what's this? |
Type II: Antibody Dependent Cellular Cytotoxicity
|
|
what's type II hypersensitivity rxn where Antibody has natural
ligand activity? |
Graves disease
|
|
what's type II hypersensitivity rxn where Antibody has natural
ligand blocking activity? |
Myasthenia gravis
|
|
what Diseases associated with Type II antibody-mediated reactions affects Type IV collagen?
|
goodpasture's syndrome
|
|
what Diseases associated with Type II antibody-mediated reactions affects skin basement membrane?
|
Bullous pemphigoid
|
|
what Diseases associated with Type II antibody-mediated reactions affects intrinsic factor?
|
pernicious anemia
|
|
what Diseases associated with Type II antibody-mediated reactions affects antibodies against streptococcus cross react with heart?
|
Acute rheumatic fever
|
|
what Diseases associated with Type II antibody-mediated reactions affects Rh D antigen?
|
Erythroblastosis fetalis
|
|
what Diseases associated with Type II antibody-mediated reactions affects ABO and minor antigens?
|
Transfusion reactions
|
|
what are Granulomatous lesions that follow necrosis/degenerative phase and precedes fibrosis?
|
Aschoff Bodies:
Hallmark of Rheumatic Fever |
|
For Rheumatic Fever, Ab’s against M-protein of Grp A Strep cross-react with : _________
|
cardiac myofiber protein myosin, heart muscle glycogen and smooth muscle cells of arteries, and perivascular connective tissue
|
|
The Aschoff body represents an intermediate step that heralds the beginning of the ________
|
repair process for the type II mediated response
|
|
With Rheumatic Fever, the initial cardiac lesion is one of ________
|
degeneration, with fibrinoid necrosis and acute inflammation
|
|
The third and final step in Rheumatic Fever is __________--
|
fibrosis (scarring)
|
|
With continued cross-reacting Ab production, chronic Rheumatic Fever is characterized by _______________
|
repeated acute inflammatory lesions with fibrinoid necrosis, Aschoff body formation and fibrinous resolution
|
|
The reaction in the tissue is characterized by necrosis, with deposits of “fibrinoid” and an infiltrate of PMNs
|
Type III Prototype: Acute post-streptococcal
glomerulonephritis |
|
key diff b/w type II and type III?
|
II: reacts to antigens on cells and tissues
III: reacts to circulating antigens |
|
what's disease ex for type II?
|
Goodpasture Syndrome
Anti-Glomerular BM (collagen IV) *smooth pattern |
|
what's disease ex for type III?
|
Acute post-streptococcal
GN / SLE *Granular pattern |
|
what type is Cell mediated hypersensitivity
No Antibodies? |
type IV
|
|
what cytokines are involved in Delayed type hypersensitivity
(Granuloma, tuberculin reaction) Activated macrophages / histiocytes? |
CD4+ Th1/Th17
|
|
what cytokines are involved in Direct cell cytotoxity (graft rejection & virus infection): Perforin/granzyme & FAS/FASL?
|
CD8+ CTL
|
|
in type IV hypersensitivity, what respond to tissue antigens by secreting cytokines that stimulate inflammation and activate phagocytes, leading to tissue injury. ?
|
CD4+ TH1 cells (and sometimes CD8+ T cells, not shown)
|
|
in type IV hypersensitivity, what contributes to inflammation by recruiting neutrophils (and, to a lesser extent, monocytes). ?
|
CD4+ TH17 cells
|
|
what is Reddening and induration peaking at 24-72 hrs.
and Perivascular infiltration of T cells (CD4+) and mononuclear phagocytes “perivascular cuffing” ? |
Classic Tuberculin Reaction (PPD)
|
|
what directly kills tissue cells?
|
CD8+ cytotoxic T lymphocytes (CTLs)
|
|
what's good and bad about CD8+ cytotoxic T lymphocytes (CTLs) directly kill tissue cells. ?
|
The Good:
Likely important in clearing of virally infected cells / intracellular pathogens & tumor immune surveillance. The Bad: Important in mediating graft rejection (Direct Pathway) and some autoimmune diseases |
|
Chronic Type IV reactions to persistant or nondegradable Ags (TB and foreign bodies (e.g. sutures) lead to __________ inflammation.
|
granulomatous
|
|
what's :
Preformed antidonor antibody (ABO incompatibility). RARE Characterized by Ab: Complement in endothelium Gross: Pale/cyanotic non-functioning organ Histology: Rapid thrombotic vasculitis w/ PMN perivascular infiltrates/ischemic necrosis |
hyperacute rejection
|
|
can chronic rejection occur with immunosuppressive therapy?
|
YES
|
|
what are the key pts of the direct pathway of rejection?
|
More prominent in acute rejection
1. Graft APCs present graft Ags to both CD4 (MHCII) & CD8 (MHCI). 2. Type IV CD8+ cytoxic T-cell mediated cell killing is prominent. Cause of tubular damage in acute & chronic rejection. 3. CD4+ response exhibits greater Th1-mediated activation of monocytic phagocytes. |
|
what are the key pts of the indirect pathway of rejection?
|
More prominent in chronic rejection
1. Recipient APCs present graft Ags (MHCI recognized as self-thus CD8+ response suppressed) Thus, indirect rejection requires MHCII- mediated activation of CD4+ cells only. 2. Limited to CD4+ cell delayed type hypersensitivity responses mediated by cytokines |
|
in either direct or indirect pathway, Ab mediated rejection is mediated by?
|
rejection vasculitis (treat with B-cell depleting therapies), cell-mediated rejection is characterized by tubular interstitial inflammatory cells (lymphocytes and mononuclear cells).
|
|
what's this? Can range from Necrotizing vasculitis (more acute-Ab mediated activation of phagocytes) to less acute: Intimal thickening with inflammatory cells, foamy macrophages and smooth muscle proliferation
Need B-cell depleting therapy: |
Acute Humoral Rejection: Type II Antibody Mediated
|
|
what's this:
Transplanted T-cells recognize recipient as “foreign” and mount rejection response. Treatment with High dose steroids and anti-thymocyte globulins High mortality rate: sepsis T-cell Depletion (anti-T cell antibodies)? |
Graft vs. Host Disease
Bone Marrow Transplants |